UK scientists will grow miniature human organs from NHS patient cells to test new medicines
UK scientists are preparing to grow miniature human organs from NHS patients’ cells in a major push to improve drug testing and reduce the use of animals in medical research.
The £20m project, based in Cambridge and funded by the Medical Research Council, will create standardised human tissue models that can be used by researchers and pharmaceutical companies to test how diseases behave and how medicines work.
The miniature human organs, known as organoids, are tiny clumps of tissue grown in the laboratory. Although they are smaller than a millimetre, they can reflect important features of real organs, including how tissues change during disease and how they respond to potential treatments.
Researchers believe the approach could make drug development more accurate because the tests are based on human biology rather than animal models.
For decades, animals have been used to study disease and test new medicines before human trials. But scientists say that many human illnesses do not appear in animals in the same way, and some do not occur in animals at all.
That gap can cause major problems. Historically, more than 90% of drugs that pass animal testing later fail in human trials, raising questions about how well animal studies predict what will happen in people.
The new Cambridge hub will work with scientists across the UK to build a library of validated organoids. These models will be made available to academics and the pharmaceutical industry, with the aim of identifying better treatments more quickly.
Embed from Getty Images
The work is also expected to help doctors understand why the same disease can vary so much between patients. By growing organoids from diseased human tissue, researchers may be able to see which drugs work for which patients and which treatments are unlikely to help.
Professor Matthias Zilbauer, from the Cambridge Stem Cell Institute, said the shift could have a major effect on how new medicines are developed. He stressed that animal use would not disappear completely in the near future, because some questions still cannot be answered with lab-grown models, but said the reduction could be significant.
The project will begin with organoids for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Other teams are expected to focus on tumour organoids for cancer research and brain organoids for neurological conditions.
Scientists will also grow different types of human tissue, from beating heart cells to electrically active brain cells.
The work forms part of a wider government plan to speed up the reduction of animals used in research. The strategy includes new approach methodologies, known as Nams, such as organoids, organs-on-a-chip and artificial intelligence tools that can process biological data and model disease.
The scale of animal testing in Britain remains large. Last year, there were 2.54m scientific procedures involving animals, down 3.8% on the previous year. More than 90% involved mice, rats, fish and birds, while 1% involved specially protected species such as cats, dogs, horses and monkeys.
A further £2m has also been awarded by Innovate UK to support nine projects aimed at reducing the use of animals, including dogs and monkeys, in safety testing.
One company, VivoSphere, is developing heart cells grown in tiny gel spheres to spot possible heart toxicity earlier in drug development. Traditional heart safety tests can involve dozens of animals, including guinea pigs, rabbits and dogs.
Supporters of the approach say the benefits could be both ethical and scientific. If harmful drugs can be detected earlier, fewer animals may be needed, and fewer patients may be exposed to medicines that are unlikely to work or could cause harm.
For patients, the bigger promise is more personalised treatment. Miniature human organs grown from patient cells could help researchers move beyond one-size-fits-all testing and towards medicines matched more closely to individual disease biology.
The Cambridge project is still at an early stage, but it points to a clear shift in medical research: fewer assumptions from animal models, and more direct testing on human tissue.